PLAU and breast cancer: Uhl et al report that heteromerization of the serine protease urokinase‐type plasminogen activator (uPA) and the serpin plasminogen activator inhibitor‐1 (PAI‐1) enforces the trafficking of pro‐tumorigenic neutrophils to malignant lesions in highly aggressive subtypes of breast cancer.